Claude Steriade, MD
Neurology · Cleveland, OHNPI 1013369446
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Neurelis, Inc. at 38.6% of the total. 2025 is the largest year on record at $19,011, 6.9 times the $2,770 reported in 2022.
Across 63 payments — averaging $829.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurelis, Inc.$20K
- UCB SA$11K
- UCB, Inc.$11K
- SK Life Science, Inc.$4K
- Neurocrine Biosciences, Inc.$4K
- Jazz Pharmaceuticals Inc.$2K
Across 33 payments — averaging $10,284 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$186K
- Genentech, Inc.$88K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$57K
- AbbVie$9K
What the payments were for
- Consulting fees$28,76655%
- Speaking & faculty fees$21,88642%
- Travel & lodging$4661%
- Food & beverage$1,1372%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurelis, Inc. | 18 | $20,152 |
| UCB SA | 10 | $11,095 |
| UCB, Inc. | 9 | $10,625 |
| SK Life Science, Inc. | 11 | $4,001 |
| Neurocrine Biosciences, Inc. | 8 | $3,900 |
| Jazz Pharmaceuticals Inc. | 7 | $2,482 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,254 in reported general payments places this provider in the 85th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FinteplaFenfluramine Hcl | 38 | $685,995 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $250,607 |
| XcopriCenobamate | 125 | $243,309 |
| EpidiolexCannabidiol (Cbd) | 48 | $201,744 |
| AptiomEslicarbazepine Acetate | 21 | $98,948 |
| OnfiClobazam | 31 | $86,592 |
| VimpatLacosamide | 72 | $74,416 |
| BriviactBrivaracetam | 37 | $73,686 |
| Keppra XrLevetiracetam | 26 | $58,484 |
| FycompaPerampanel | 32 | $41,238 |
| FelbatolFelbamate | 25 | $37,489 |
| ValtocoDiazepam | 27 | $35,808 |
| LamictalLamotrigine | 40 | $34,912 |
| ZonegranZonisamide | 14 | $29,839 |
| Oxtellar XrOxcarbazepine | 17 | $26,600 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla, Vimpat, Briviact, Nayzilam | $10,625 | $850,230163 claims |
| SK Life Science, Inc.Xcopri | $4,001 | $243,309125 claims |
| Neurelis, Inc.Valtoco | $20,152 | $35,80827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 702 neurology providers in Ohio.
Other neurology in Cleveland
- Imad NajmCleveland$373K
- Hesham AbboudCleveland$363K
- Robert BermelCleveland$302K
- Eric BaronCleveland$297K
- Robert FoxCleveland$296K
- Aarushi SunejaCleveland$269K
- Mary WillisCleveland$254K
- Benjamin WalterCleveland$210K
- Aasef ShaikhCleveland$186K
- Maryann MaysCleveland$173K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.